RAPP

Rapport Therapeutics, Inc. (RAPP) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system (CNS) disorders using its RAP technology platform. The company's lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator being developed for focal epilepsy. In June 2024, the company completed its Initial Public Offering (IPO) and a concurrent private placement, transitioning from a private to a public entity.

Key Financial Metrics

Note: The company has no revenue. Liquidity figures exclude restricted cash of $105,000.

Material Changes vs. Prior Period

• Capital Raise: The most significant change was the completion of the IPO and concurrent private placement in June 2024, generating net proceeds of approximately $157.6 million. This resulted in a substantial increase in cash and short-term investments compared to the prior year.
• Expense Growth: Operating expenses increased significantly year-over-year. R&D expenses rose by $10.97 million for the quarter (133% increase) and $19.57 million for the six months (227% increase). This was driven by Phase 2a trial start-up costs for RAP-219, toxicology studies, and increased headcount.
• Non-Cash Items: The six-month 2024 period included a $7.39 million expense related to the change in fair value of the Series B preferred stock tranche right liability prior to its settlement. This item was not present in the same form in the prior year.
• Equity Structure: All outstanding Series A and Series B convertible preferred stock was converted to common stock immediately prior to the IPO closing.

Guidance, Outlook, and Risks

• Clinical Outlook: The company is on track to initiate a Phase 2a proof-of-concept trial for RAP-219 in adult patients with drug-resistant focal epilepsy in the third quarter of 2024, with topline results expected in mid-2025. Phase 2a trials for peripheral neuropathic pain and bipolar disorder are planned for the second half of 2024 and 2025, respectively.
• Liquidity Runway: Management expects that existing cash, cash equivalents, and short-term investments ($336.1 million) will be sufficient to fund operating expenses and capital expenditure requirements through at least the end of 2026.
• Key Risks:
  • Development Risk: High uncertainty regarding clinical trial outcomes; failure to demonstrate efficacy or safety could halt development.
  • Capital Needs: Despite the recent IPO, the company will require substantial additional capital in the future to complete development and commercialization.
  • Third-Party Dependence: Reliance on third parties for clinical trials (including NeuroPace for data collection) and manufacturing.
  • Regulatory Risk: Lengthy and unpredictable approval processes by the FDA and EMA.

Investor Verification Checklist

• Phase 2a Trial Initiation: Verify the actual start date of the RAP-219 Phase 2a trial in Q3 2024 and patient enrollment progress.
• Burn Rate Analysis: Monitor quarterly operating expenses to ensure the projected runway through 2026 remains valid given the increased spending on clinical trials.
• NeuroPace Partnership: Confirm the status of the data collection agreement with NeuroPace, which is critical for the primary endpoint of the focal epilepsy trial.
• Stock-Based Compensation: Review future stock-based compensation expenses as the company scales its workforce post-IPO.
• Intellectual Property: Assess the status of the Janssen license agreement and any potential milestone payment obligations.